von Tobias Borgers | Apr. 11, 2024 | Glaxo
Trelegy Ellipta is approved as a maintenance treatment for COPD and asthma in the US. Image Credit: MAXSHOT.PL / Shutterstock. Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone...
von Tobias Borgers | Apr. 11, 2024 | Glaxo
GSK’s respiratory portfolio focuses on therapies for diseases characterised by high eosinophil levels or high T2 inflammation. GSK has successfully concluded the acquisition of Aiolos Bio in a deal that could reach $1.4bn, marking a significant expansion of GSK’s...
von Tobias Borgers | März 21, 2024 | Boehringer
Global animal health leader adopts Veeva Vault Clinical and Veeva Vault RIM for greater efficiency, visibility, and speedPLEASANTON, Calif., Feb. 14, 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim has selected Veeva...
von Tobias Borgers | März 21, 2024 | Bayer
Bayer has announced a licensing agreement with BridgeBio Pharma to commercialise acoramidis as a treatment for patients living with transthyretin amyloid cardiomyopathy (ATTR-CM). As part of the deal, Bayer will receive an exclusive license to commercialise acoramidis...
von Tobias Borgers | März 21, 2024 | Boehringer
Bei der Forschung nach neuen therapeutischen Antikörpern setzt Boehringer Ingelheim auf die Unterstützung durch KI. Foto: Corona Borealis Studio – shutterstock.comUm die Entwicklung neuer Medikamente zu beschleunigen, setzt das 1885 gegründete...
von Tobias Borgers | Feb. 23, 2024 | Glaxo
GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. As previously...
